CagriSema: What the REDEFINE Trial Data Actually Show

Search "cagrilintide" and you'll find both legitimate trial coverage and gray-market sellers offering to ship it to you today. Only one of those is telling the truth about what CagriSema actually is: an investigational Novo Nordisk combination drug, not an FDA-approved product, with real Phase 3 data now published. Here's what the trials actually found — and why the gap between "real trial results" and "available for purchase" is exactly the kind of gap this site exists to flag.

What CagriSema actually is

CagriSema combines two mechanisms in one weekly injection: semaglutide, the GLP-1 receptor agonist already familiar from Ozempic and Wegovy, and cagrilintide, an amylin analog — a different hormone pathway involved in satiety and gastric emptying that no currently-approved obesity drug targets directly. The rationale for combining them is that amylin and GLP-1 signaling work through different receptors, so pairing them was hypothesized to produce a larger effect than either drug alone. The REDEFINE trials are the Phase 3 program built to test that hypothesis.

REDEFINE-1: adults with obesity, no diabetes

REDEFINE-1 randomized 3,417 adults with obesity or overweight (without type 2 diabetes) across four arms — CagriSema, semaglutide alone, cagrilintide alone, and placebo — and followed them for 68 weeks¹. The headline result: CagriSema produced a mean body weight reduction of 20.4% from baseline, versus 3.0% on placebo, a treatment difference of 17.3 percentage points (95% CI, -18.1 to -16.6; P<0.001)¹. Participants on CagriSema were significantly more likely to reach every weight-loss threshold the trial measured — 5%, 20%, 25%, and 30% — than those on placebo (all P<0.001)¹. Gastrointestinal adverse events were common, as they are across this drug class: 79.6% of the CagriSema group reported a GI event versus 39.9% on placebo, though the trial characterized them as "mainly transient and mild-to-moderate in severity"¹.

REDEFINE-2: adults with obesity and type 2 diabetes

A second trial, REDEFINE-2, tested the same combination specifically in 1,206 adults with overweight or obesity and type 2 diabetes across 12 countries, also over 68 weeks². Weight loss was smaller in this population — a pattern consistent across the GLP-1 class, where diabetes tends to blunt the magnitude of weight reduction compared with non-diabetic populations — at a mean 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (P<0.001)². On glycemic control, 73.5% of the CagriSema group reached an HbA1c of 6.5% or lower, versus 15.9% on placebo². GI adverse events again predominated: 72.5% versus 34.4% on placebo, again described as mostly transient and mild-to-moderate².

How this stacks up against the drugs already on the market

A 20.4% average weight reduction is a genuinely large effect size — larger than tirzepatide's roughly 20.2% in the SURMOUNT-5 head-to-head trial against semaglutide, though CagriSema and tirzepatide haven't been tested directly against each other, so that comparison is cross-trial, not head-to-head; see semaglutide vs tirzepatide: which is cheaper and more effective for how the two approved drugs actually compare today. What CagriSema represents, if it's approved, is a genuine step beyond the current ceiling — not an incremental tweak.

What this doesn't mean: it isn't for sale, and anything claiming to be "cagrilintide" today should raise a flag

This is the part that matters most for your wallet. CagriSema has not completed FDA review and is not an approved product as of this writing — the REDEFINE trials are registration studies, the step before a regulatory filing, not evidence of market availability. That means any compounding pharmacy, research-chemical seller, or "peptide" vendor offering "cagrilintide" for sale right now is not selling an FDA-approved medication, and is very likely not selling verified, quality-controlled cagrilintide at all — the same red flag covered in is cheap compounded GLP-1 safe? and how to verify a compounding pharmacy is legitimate. An unapproved peptide bought online carries none of the manufacturing oversight, purity testing, or dosing accuracy that the REDEFINE trial material did — the trial results above say nothing about what you'd actually be injecting from an unregulated seller.

Where this fits the bigger access picture

CagriSema joins retatrutide as one of the next-generation obesity drugs generating real trial data without being available to buy — see retatrutide: is it available, and is it safe to buy now? for how that comparison plays out for a different investigational drug. Until an FDA approval actually happens, the legitimate, verified options remain the already-approved GLP-1s tracked on our price boards.

Where this fits your decision today

If cost or effectiveness is driving you toward looking at CagriSema now, the honest answer is that today's real, purchasable options are the already-approved drugs — compare current pricing on our semaglutide and tirzepatide price boards, and see how we score program legitimacy in our Value Score methodology. We'll update this page if and when CagriSema receives FDA approval.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.